指南与共识骨质疏松与代谢性骨病骨肿瘤

癌症幸存者骨健康管理:临床指南的系统综述

Management of bone health in cancer survivorship: a systematic review of clinical guidelines.
指南 / 共识 · Osteoporos Int · 2026-03-24

指南质量多为中等,缺乏整体多学科推荐。

要点

  • 三分之二指南包含生活方式推荐(多为维生素D和钙补充)。
  • 76%指南推荐筛查(多为DXA骨密度),89%推荐药物干预(双膦酸盐和地舒单抗最常见)。

核心结论

  • 指南间质量存在差异,许多缺乏整体、多学科骨健康管理推荐。
  • 建议进一步制定指南以支持具有多重风险因素的患者,并纳入管理策略以减轻癌症相关骨丢失与年龄相关骨退化的叠加效应。

研究设计与样本

  • 系统综述,检索PubMed、EMBASE、CINAHL和Scopus四个电子数据库。

主要发现

  • 三分之二指南包含生活方式推荐,最常见为维生素D和钙补充。
  • 76%指南包含筛查推荐,最常见为通过DXA测量骨密度。
  • 89%指南包含药物干预推荐,最常见为双膦酸盐和地舒单抗。
  • 使用AGREE II工具,42部指南评为中等质量,23部为高质量,在范围和目的、清晰性以及编辑独立性领域得分较强。

关键数值与推荐

  • 76%推荐筛查(DXA骨密度最常见),三分之二推荐生活方式(维生素D和钙补充最常见)。
  • AGREE II评价:42部中等质量,23部高质量。

临床怎么用

  • 临床可参考多数指南推荐的维生素D和钙补充、DXA筛查及双膦酸盐/地舒单抗药物干预。
  • 需注意仅约半数指南覆盖全部三个领域,应结合多学科团队制定整体骨健康管理方案。
  • 对具有多重风险因素的癌症幸存者,应关注癌症相关骨丢失与年龄相关骨退化的叠加效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Accelerated bone loss is a side effect of many anticancer treatments, posing significant health challenges for cancer survivors. The aim of this systematic review was to evaluate and synthesize recommendations for the management of bone health, specifically fracture and osteoporosis risk, in clinical guidelines for people with cancer. METHODS: Searches related to bone health clinical guidelines for cancer patients were conducted in four electronic databases (PubMed, EMBASE, CINAHL, and Scopus). Data extraction was performed independently by multiple authors. Quality appraisal was performed using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) instrument. Guidelines were categorized into three key focus areas (pharmacological interventions, screening, and lifestyle modifications) and compared across cancer types. RESULTS: A total of sixty-five guidelines were included in the systematic review. Two-thirds of guidelines included recommendations related to lifestyle (most commonly vitamin D and calcium supplementation), 76% related to screening (mostly bone mineral density via DXA), and 89% related to pharmacological intervention (most commonly bisphosphonates and denosumab). Fifty-four percent included recommendations in all three domains. Using the AGREE II tool, 42 guidelines were rated moderate and 23 high with strong scoring in domains of Scope and Purpose, Clarity of Presentation and Editorial Independence. CONCLUSIONS: Findings highlight variations in guideline quality, with many lacking holistic, multidisciplinary recommendations for bone health management. Further development of guidelines supporting patients impacted by multiple risk factors, and the inclusion of management strategies to mitigate compounding effects of cancer-related bone loss and age-related bone degradation among cancer patients, is recommended.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Li VKC, Cosgrove S, Collins K, et al. Management of bone health in cancer survivorship: a systematic review of clinical guidelines. Osteoporos Int. 2026. PMID: 41872365. doi:10.1007/s00198-026-07924-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。